Authors

Latest:

The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The Network

Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.

Muhamad Alhaj Moustafa, MD, MS

Latest:

Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCL

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.

Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

Latest:

Precision Medicine: Key Updates for Treatment of NSCLC

William (Bill) Stokes, MD

Latest:

Dr Stokes on Radiation Vs Surgery in HPV+ OPSCC

William (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.

Christopher Wee, MD

Latest:

Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

Mark Levis, MD, PhD, Johns Hopkins University School of Medicine

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Paul A. DiSilvestro, MD

Latest:

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.

Filipia Lynce, MD

Jessica Stine, MD

Jessica Stine, MD, medical director, Gynecologic Oncology, Florida Cancer Specialists & Research Institute

Latest:

Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD

Drs Bustamante and Stine discuss their journeys toward oncology careers, the importance of peer mentorship, and the evolving nature of work-life balance.

I-Chia (Daniel) Liu, MD

Latest:

Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal Cancer

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Neil H. Bander, MD

Latest:

Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Nam Bui, MD

Latest:

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Alireza Ghoreifi, MD

Alireza Ghoreifi, MD, Duke University Department of Urology, and member of the Society of Urologic Oncology (SUO) Fellow.

Latest:

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Kala Visvanathan, MD, MBBS, MHS

Latest:

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.

Alex McDaniel

Latest:

Seeing Medicine Through the Eye of an Artist

For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.

Francesco Di Meo, PhD

Latest:

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Jérôme Fayette, MD, PhD

Latest:

Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCC

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Lori A. Leslie, MD, Hackensack University Medical Center

Latest:

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Idoroenyi Amanam, MD

Idoroenyi Amanam, M.D.,

Latest:

Dr Amanam on the Real-World Efficacy of First-Line Luspatercept vs Erythropoiesis-Stimulating Agents in Lower-Risk MDS

Idoroenyi Amanam, MD, discusses the efficacy of first-line luspatercept vs erythropoiesis-stimulating agents in real-world patients with lower-risk MDS.

Jeremy M. Pantin, MD

Latest:

Dr Pantin on the Evolving Treatment Paradigm in PNH

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.